Gossamer Bio Inc. (GOSS)
GOSS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1728117/000172811726000017/0001728117-26-000017-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GOSS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001728117 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $48.5M |
| Net income | -$170.4M |
| Operating income | -$170.7M |
| Net margin | -351.5% |
| Operating margin | -352.2% |
| Revenue growth | -57.7% |
| Cash | $37.7M |
| Total assets | $172.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, these conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-10 |
| Cash and burn | $51.2M cash; operating cash flow -$39.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 6,116,390 (2026-11-07); 231,456,247 a year earlier; 225,409,314 three years earlier. 1y figure adjusted for split (1-for-80 overall); 3y figure adjusted for split (1-for-80 overall). | Cover page 2026-11-07 |
| Reverse splits, 3 years | 1; latest 1-for-80 on 2026-09-11 | Source 2026-09-11 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-01-28 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-09 |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $38.4M | -$48.1M | -$29.6M | $51.2M | $37.1M | $78.4M | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | $9.2M | $16.9M | -$39.4M | $41.1M | $36.1M | $53.3M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $17.0M | -$46.7M | -$38.7M | $41.0M | No debt tags | $55.5M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $13.8M | -$47.2M | -$48.3M | $37.7M | $0 | $48.5M | 10-K 2026-03-17 |
| Q3 2025 2025-09-30 | $13.3M | -$48.2M | -$36.2M | $8.9M | No debt tags | $44.1M | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $11.5M | -$38.3M | -$47.1M | $26.3M | No debt tags | $40.2M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $9.9M | -$36.6M | -$39.7M | $29.0M | No debt tags | $124.6M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $9.4M | -$33.0M | -$35.5M | $46.1M | $0 | $114.7M | 10-K 2026-03-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-16 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-09-16 |
Source: SEC EDGAR submissions feed, 490 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.3% |
| 1 month | +12.4% |
| 3 months | -19.3% |
| Year to date | -95.6% |
| 1 year | -94.5% |
| From 52-week high | -96.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TENX | Tenax Therapeutics Inc. | $1.48 | -8.64% | $67.4M |
| ZYBT | Zhengye Biotechnology Holding Limited | $1.43 | -4.67% | $67.8M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| ACRV | Acrivon Therapeutics Inc. | $1.46 | +0.69% | $62.6M |
| MAIA | MAIA Biotechnology Inc. | $1.01 | +1.00% | $62.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier